 Pyrroles
"Pyrroles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
| Descriptor ID |
D011758
|
| MeSH Number(s) |
D03.383.129.578
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrroles".
Below are MeSH descriptors whose meaning is more specific than "Pyrroles".
This graph shows the total number of publications written about "Pyrroles" by people in this website by year, and whether "Pyrroles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 | | 1996 | 1 | 3 | 4 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 2 | 1 | 3 | | 2002 | 1 | 1 | 2 | | 2003 | 3 | 1 | 4 | | 2004 | 4 | 5 | 9 | | 2005 | 8 | 2 | 10 | | 2006 | 1 | 2 | 3 | | 2007 | 6 | 4 | 10 | | 2008 | 3 | 3 | 6 | | 2009 | 9 | 2 | 11 | | 2010 | 2 | 3 | 5 | | 2011 | 3 | 3 | 6 | | 2012 | 6 | 5 | 11 | | 2013 | 5 | 3 | 8 | | 2014 | 2 | 6 | 8 | | 2015 | 4 | 2 | 6 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 4 | 6 | | 2018 | 1 | 3 | 4 | | 2019 | 2 | 3 | 5 | | 2020 | 0 | 2 | 2 | | 2021 | 2 | 3 | 5 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrroles" by people in Profiles.
-
Alegret N, Dominguez-Alfaro A, Mecerreyes D, Prato M, Mestroni L, Pe?a B. Neonatal rat ventricular myocytes interfacing conductive polymers and carbon nanotubes. Cell Biol Toxicol. 2023 08; 39(4):1627-1639.
-
Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
-
Kibbie J, Kines K, Norris D, Dunnick CA. Oral tofacitinib for the treatment of alopecia areata in pediatric patients. Pediatr Dermatol. 2022 Jan; 39(1):31-34.
-
Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langou?t-Astri? C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 10; 20(10):2049-2060.
-
Casalvieri KA, Matheson CJ, Warfield BM, Backos DS, Reigan P. N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors. Bioorg Med Chem. 2021 07 01; 41:116220.
-
Lee H, Li T, Wisell J, Schowinsky J, Robinson WA. Avapritinib for Cutaneous Mastocytosis. Acta Derm Venereol. 2021 Jan 05; 101(1):adv00362.
-
Taylor JP, Armitage LH, Aldridge DL, Cash MN, Wallet MA. Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA. Biol Open. 2020 12 21; 9(12).
-
Pasupneti S, Tian W, Tu AB, Dahms P, Granucci E, Gandjeva A, Xiang M, Butcher EC, Semenza GL, Tuder RM, Jiang X, Nicolls MR. Endothelial HIF-2a as a Key Endogenous Mediator Preventing Emphysema. Am J Respir Crit Care Med. 2020 10 01; 202(7):983-995.
-
Le Cras TD, Abman SH. Early Disruption of VEGF Receptor Signaling and the Risk for Adult Emphysema. Am J Respir Crit Care Med. 2020 03 01; 201(5):620-621.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|